About Us
Animal Transgenic Facility
Located in Verónica, Buenos Aires, our Animal Transgenic Facility is composed of specialized sectors dedicated to cutting-edge biotechnology for human health applications.
- Bovine Embryology Laboratory
In this laboratory, we carry out cloning and reproduction processes for genetically modified bovines to feed the GMB Platform. Genes of interest are inserted into the animals, resulting in the efficient production of recombinant proteins for humans.
- Milking Facilities
We keep genetically modified cows in specially equipped milking facilities, where they produce milk containing the recombinants proteins. These proteins are then purified and processed to create affordable therapeutic medicines.
- Molecular Biology Laboratory
Here, we develop cutting-edge biotechnological techniques, such as CRISPR-Cas9 — a powerful genetic engineering tool that allows us to edit and correct the genome of virtually any cell.
Our History
Biomill is a spin-off from Biosidus. Currently, both companies keep a tight relationship and collaborate in different developments and projects.
Biomill starts with the acquisition of genetically modified bovine animals GMB technology, which is then enhanced with other products and services.
1983: Biosidus is established in Argentina with the development and commercialization of recombinant proteins for human use.
1990: Biosidus expands its operations and product portfolio, reaching more than 40 countries in the world.
2000: Biosidus develops genetically modified animal technology, cloning the first cow in Latin America.
2018: Biosidus teams up with a Private Equity focusing on biosimilar medicines developed using conventional platforms.
2019: Biomill acquires genetically modified animal technology, patents, equipment and brands from Biosidus.
2025: Nowadays, Biomill has a strong portfolio of pharmaceutical projects and products, including hGH, lysosomal enzymes and monoclonal antibodies.
Our team
Several Biomill collaborators joined the company coming from Biosidus, bringing along sound knowledge in the Biotechnology and Commercial areas within Emerging Markets, and particularly in Latin America.
Santiago García Belmonte
President and shareholder of Biomill and President and shareholder of the Biosidus Group. Over the past 15 years, he led the successful consolidation of Biosidus in Argentina and its international expansion to more than 50 countries.
Dr. Gustavo Mahler
Scientist who significantly contributed to the development of the first biosimilar monoclonal antibody in Argentina. He held key positions at Bayer Healthcare for 15 years. He currently serves on the boards of directors of several pharma-related companies. He collaborates with Biomill on various human health projects.
Martín Gravano
CEO of Biomill, with 30 years of experience in the pharmaceutical industry. Former Global Director of Cardiology at Merck Serono KGaA. Former Commercial Director of Emerging Markets of Biosidus, contributing to the international expansion of its products in the world. He is an extensive knowledge of the Latin American markets.
Lic. Claudio Santos
Head of Embriology. Claudio holds a degree in Biological Sciences specializing in embriology and cloning. He was part of the team that first cloned a cow and a horse in Latin America.
With more than 25 years of experience in the field, he is recognized as one of the world leaders in his specialty, having received multiple awards and recognitions for his innovative approach to biotechnology.
Dr. Andrés Bercovich
Head of New Technologies & Projects. Andres holds a PhD in Biochemistry from the University of Buenos Aires, with over 25 years of experience in biotechnology and pharmaceuticals. His diverse field, which ranges from R&D to Business Development, is one of his key assets.
Lic. Lara Bertoncin
Head of R&D. Lara is responsible for leading and coordinating the research and development activities at the company. She holds a degree in Molecular Biology, specializing in CRISPR-Cas9 and other advanced techniques. Gene editing and genetic modification are areas of particular interest for Biomill under her leadership.
Med. Vet. Mauricio Berro
Tech Operations Manager. Mauricio is a veterinarian specializing in animal health and reproduction. He has over 15 years of experience working with genetically modified cattle and their regulations in Argentina.
Federico Alais
Biomill Business Development Director. He has more than 10 years of experience in the pharmaceutical industry accompanying the international expansion process of Biosidus. He also has extensive knowledge in Biotechnology and Agribusiness, having worked at INDEAR and other related companies.
Biomill actively collaborates with an extensive network of scientists in Argentina and around the world. We do so with a dual purpose: to contribute to the development of basic science and at the same time to develop specific and affordable medicines and services aimed at the needs of humanity.
Biomill. Technology at the service of Health
Aligned with our operating model, our facilities are decentralized and close to our customers.